This study examines whether adding a drug called JNJ-90301900 to the usual treatment for a type of lung cancer, called non-small cell lung cancer (NSCLC), can improve patient outcomes. Treatment includes chemoradiation (a combination of chemotherapy and radiation therapy) and consolidation immunotherapy (an additional treatment to strengthen the immune system). The study focuses on patients with advanced lung cancer that cannot be removed by surgery.

Eligibility: Participants should be able to receive standard lung cancer treatments and meet specific health criteria, such as having a confirmed NSCLC diagnosis and a good performance status, which assesses daily activity ability.

Exclusions: The study does not include individuals with certain health conditions, like severe heart disease or recent cancer history other than NSCLC, and those with certain allergies.

• Study Duration: Participation involves long-term treatment and monitoring.
• Visit Requirements: Participants must attend regular medical check-ups.
• Risks: Potential side effects from the new drug and treatments are possible.